The primary objective is to evaluate the dose-response effects of two different rehabilitation settings, characterized by different workload (measured as energy expenditure), on blood BDNF levels. conditions: Parkinson Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Aerobic exercise measure: Change in Brain-derived neurotrophic (BDNF) concentration assessed in peripheral blood samples (ng/mL) measure: Change in Brain-derived neurotrophic (BDNF) concentration assessed in peripheral blood samples (ng/mL) measure: Change in Brain-derived neurotrophic (BDNF) concentration assessed in peripheral blood samples (ng/mL) measure: Change in peripheral biomarker Insulin-like Growth Factor-1 (IGF-1) measure: Change in peripheral biomarker Insulin-like Growth Factor-1 (IGF-1) measure: Change in peripheral biomarker Insulin-like Growth Factor-1 (IGF-1) measure: Change in peripheral biomarker Fibronectin type III domain-containing protein 5 (FNDC5)/Irisin measure: Change in peripheral biomarker Fibronectin type III domain-containing protein 5 (FNDC5)/Irisin measure: Change in peripheral biomarker Fibronectin type III domain-containing protein 5 (FNDC5)/Irisin measure: Change in peripheral biomarker of inflammation measure: Change in peripheral biomarker of inflammation measure: Change in peripheral biomarker of inflammation measure: Change in platelet distribution width (PDW) and number of platelets assessed by peripheral blood samples measure: Change in platelet distribution width (PDW) and number of platelets assessed by peripheral blood samples measure: Change in platelet distribution width (PDW) and number of platelets assessed by peripheral blood samples measure: Change in blood lactate levels assessed using finger-stick capillary blood samples measure: Change in gut microbial diversity (species diversity %) assessed by next-generation sequencing (NGS) of the V3-V4 region of the 16S rDNA gene measure: Change in motor symptoms - MDS-UPDRS part II measure: Change in motor symptoms - MDS-UPDRS part II measure: Change in motor symptoms - MDS-UPDRS part II measure: Change in motor symptoms - MDS-UPDRS part III measure: Change in motor symptoms - MDS-UPDRS part III measure: Change in motor symptoms - MDS-UPDRS part III measure: Change in motor symptoms - MDS-UPDRS part IV measure: Change in motor symptoms - MDS-UPDRS part IV measure: Change in motor symptoms - MDS-UPDRS part IV measure: Change in movement analysis - stride length measure: Change in movement analysis - stride length measure: Change in movement analysis - stride length measure: Change in movement analysis - cadence measure: Change in movement analysis - cadence measure: Change in movement analysis - cadence measure: Change in movement analysis - propulsion measure: Change in movement analysis - propulsion measure: Change in movement analysis - propulsion measure: Change in movement analysis - Time Up and Go (TUG) measure: Change in movement analysis - Time Up and Go (TUG) measure: Change in movement analysis - Time Up and Go (TUG) measure: Change in walking capacity measure: Change in walking capacity measure: Change in walking capacity measure: Change in postural instability measure: Change in postural instability measure: Change in postural instability measure: Change in cognitive function - Montreal Cognitive Assessment (MoCA) measure: Change in cognitive function - Montreal Cognitive Assessment (MoCA) measure: Change in cognitive function - Montreal Cognitive Assessment (MoCA) measure: Change in cognitive function - Mini-Mental Examination (MMSE) measure: Change in cognitive function measure: Change in cognitive function measure: Change in cognitive function - Frontal Assessment Battery (FAB) measure: Change in cognitive function - Frontal Assessment Battery (FAB) measure: Change in cognitive function - Frontal Assessment Battery (FAB) measure: Change in severity of depressive symptomatology measure: Change in severity of depressive symptomatology measure: Change in severity of depressive symptomatology measure: Change in non-motor symptoms measure: Change in non-motor symptoms measure: Change in non-motor symptoms measure: Change in motor fluctuations measure: Change in motor fluctuations measure: Change in motor fluctuations measure: Change in quality of life measure: Change in quality of life measure: Change in quality of life measure: Change in cortical activity measure: Change in cortical activity measure: Change in Brain Connectivity measure: Change in Brain Connectivity sex: ALL minimumAge: 30 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: San Raffaele Cassino city: Cassino state: Frosinone zip: 03043 country: Italy lat: 41.48581 lon: 13.82835 hasResults: False